Omkar is an advanced therapy leader specializing in manufacturing, supply chain & digital enablement of Advanced Therapies.
Omkar Kawalekar is a leader in Deloitte's NextGen Therapies practice, specializing in the manufacturing and supply chain of advanced therapies. With two decades of experience in life sciences and clinical research, he brings deep expertise across the full advanced therapy value chain - from clinical development through commercial-scale manufacturing and supply.
A prominent voice in the global Cell and Gene Therapy community, Omkar is widely recognized for his eminence work - including peer-reviewed publications, keynote and invited speaking engagements, and panel presentations at leading international conferences. His insights shape industry dialogue on the evolving manufacturing and supply chain landscape for cell, gene, and other next-generation therapies.
Omkar holds a PhD in Cell and Molecular Biology from the University of Pennsylvania, where his research pioneered CAR-T therapy and Immuno-Oncology. His rare combination of scientific depth, entrepreneurial experience, and strategic advisory expertise allows him to help clients navigate the complex intersection of innovation, operations, and commercialization in advanced therapies.